Hospital.Help

Boston – The CD19 antibody inebilizumab, already approved to treat another rare autoimmune disease, reduced the frequency of disease flare-ups by more than 90% in a phase 3 study in patients with IgG4-related diseases, making it possible to be the first in active ingredient approved for this indication. The results were presented at the annual meeting of the American College of Rheumatology in Washington…